These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 24666831)

  • 1. Antibody desensitization therapy in highly sensitized lung transplant candidates.
    Snyder LD; Gray AL; Reynolds JM; Arepally GM; Bedoya A; Hartwig MG; Davis RD; Lopes KE; Wegner WE; Chen DF; Palmer SM
    Am J Transplant; 2014 Apr; 14(4):849-56. PubMed ID: 24666831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab.
    Lobashevsky AL; Higgins NG; Rosner KM; Mujtaba MA; Goggins WC; Taber TE
    Transplantation; 2013 Jul; 96(2):182-90. PubMed ID: 23778648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly Sensitized Patients: Miami Transplant Institute Experience.
    Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
    Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time?
    Kozlowski T; Andreoni K
    Ann Transplant; 2011; 16(2):19-25. PubMed ID: 21716181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
    Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable Outcome of an Exclusively Posttransplant Prophylactic Strategy After Heart Transplantation in Recipients With High Immunological Risk.
    Coutance G; d'Orio V; Belin L; Bréchot N; Saheb S; Lebreton G; Bouglé A; Rouvier P; Gautreau C; Ouldammar S; Chamillard X; Huot M; Amour J; Combes A; Leprince P; Varnous S
    Transplantation; 2019 Jul; 103(7):1439-1449. PubMed ID: 30376551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of high-dose intravenous immunoglobulin on anti-HLA antibodies in sensitized kidney transplant candidates.
    Nair V; Sawinski D; Akalin E; Friedlander R; Ebcioglu Z; Sehgal V; Dinavahi R; Khaim R; Ames S; Lerner S; Murphy B; Bromberg JS; Heeger PS; Schröppel B
    Clin Transplant; 2012; 26(3):E261-8. PubMed ID: 22686949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does bortezomib influence pre-transplant desensitization therapy or benefit post-heart transplant outcomes for highly sensitized patients?
    Dhillon M; Kobashigawa JA; Kittleson M; Jain R; Patel N; Singer-Englar T; Zhang X; Hakimi M; Aintablian T; Vescio R; Dilibero D; Kransdorf E; Czer L; Nikolova AP; Patel JK
    Clin Transplant; 2024 Jan; 38(1):e15165. PubMed ID: 37837612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desensitization in the Setting of HLA-Incompatible Kidney Transplant.
    Malvezzi P; Jouve T; Noble J; Rostaing L
    Exp Clin Transplant; 2018 Aug; 16(4):367-375. PubMed ID: 29863455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
    Yuan XP; Wang CX; Gao W; Fu Q; He XS
    Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of Desensitization Therapy in Immunologically High-Risk Kidney Transplantation: Single-Center Experience.
    Sinangil A; Ucar ZA; Koc Y; Barlas S; Abouzahir S; Ecder ST; Akin EB
    Transplant Proc; 2019 Sep; 51(7):2268-2273. PubMed ID: 31358450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of desensitization protocol with and without rituximab in sensitized kidney transplant recipients.
    Green H; Nesher E; Aizner S; Israeli M; Klein T; Zakai H; Rahamimov R; Rozen-Zvi B; Mor E
    Clin Transplant; 2019 Jun; 33(6):e13562. PubMed ID: 30941818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous Immunoglobulins Alone for the Desensitization of Lung Transplant Recipients with Preformed Donor Specific Antibodies and Negative Flow Cytometry Crossmatch.
    Abdulqawi R; Alawwami M; Aldosari O; Aldosari Z; Alhuqbani M; Saleh RA; Esendagli D; Aldakhil H; De Vol EB; Alkattan K; Marquez KAH; Saleh W; Sandoqa S; Al-Mutairy EA
    Clin Transplant; 2024 Jul; 38(7):e15374. PubMed ID: 38979724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful desensitization and kidney transplantation in the presence of donor-specific anti-human leukocyte antigen antibodies in kidney transplant recipients.
    Khan MT; Hamid RB; Sarfaraz S; Lal N; Ahmed J; Luxmi S
    Saudi J Kidney Dis Transpl; 2020; 31(6):1432-1438. PubMed ID: 33565460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA desensitization with bortezomib in a highly sensitized pediatric patient.
    May LJ; Yeh J; Maeda K; Tyan DB; Chen S; Kaufman BD; Bernstein D; Rosenthal DN; Hollander SA
    Pediatr Transplant; 2014 Dec; 18(8):E280-2. PubMed ID: 25174602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients.
    Marfo K; Ling M; Bao Y; Calder B; Ye B; Hayde N; Greenstein S; Chapochnick-Friedman J; Glicklich D; de Boccardo G; Kinkhabwala M; Akalin E
    Transplantation; 2012 Aug; 94(4):345-51. PubMed ID: 22820699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens.
    Appel JZ; Hartwig MG; Davis RD; Reinsmoen NL
    Hum Immunol; 2005 Apr; 66(4):378-86. PubMed ID: 15866701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
    Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A
    Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
    Stuckey LJ; Kamoun M; Chan KM
    Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness of the combination of rituximab and high-dose immunoglobulin in the immunomodulation of sensitized kidney transplant candidates.
    Taber T; Mujtaba MA; Goggins W; Higgins N; Sharfuddin A; Yaqub MS; Mishler D; Book B; Chen J; Lobashevsky A
    Clin Transplant; 2013; 27(4):E375-82. PubMed ID: 23721524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.